COLL Collegium Pharmaceutical, Inc. logo

COLL Collegium Pharmaceutical, Inc.

Healthcare
$34.07-1.02%ClosedMarket Cap: $1.11B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

17.91

PEG

P/B

3.50

P/S

1.39

EV/EBITDA

2.71

DCF Value

$634.78

FCF Yield

29.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

60.7%

Operating Margin

23.8%

Net Margin

9.4%

ROE

26.7%

ROA

4.5%

ROIC

10.5%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$193.5M$14.5M$
Q4 null$205.4M$17.0M$
FY null$780.6M$62.9M$
Q3 null$209.4M$31.5M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$58.00

Target (Median)

$58.00

Target Range

$56.00 - $60.00

2 Strong Buy3 Buy1 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-03-20
NeedhamBuy
2026-03-19
BarclaysOverweight
2026-01-09
HC Wainwright & Co.Buy
2026-01-09
NeedhamBuy
2026-01-08

Trading Activity

Insider Trades

View All
Freund John Gordondirector
SellWed May 20
SANTINI GINOdirector
SellMon May 18
Paya Carlos Vdirector
SellMon May 18
Lurker Nancydirector
SellMon May 18
Glancy Donovan Michaeldirector
SellMon May 18

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

US

Exchange

Beta

0.76

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Peers